Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Augmentation in Schizophrenia
NCT00289861Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2003
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizophrenia comparing Risperidone with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 8 weeks. Started Feb 2003; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00289861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00289861.